Nicholas Wallingford

Nicholas Wallingford

Auto-generated profile, based on publicly available information

Nicholas Wallingford

Pfizer Global Research & Development, Drug Safety R&D, Histopathology, La Jolla, San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2008 in Nature
Verified
Journal Article
Closed access
PDF file
ZAZane B. Andrews
Zane B. Andrews
ZLZhong-Wu Liu
Zhong-Wu Liu
NWNicholas Walllingford
Nicholas Walllingford
DEDerek M. Erion
Derek M. Erion
EBErzsebet Borok
Erzsebet Borok
SDSabrina Diano
Sabrina Diano

7 August 2005 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SBStephen A Back
Stephen A Back
TTTherese M F Tuohy
Therese M F Tuohy
HCHanqin Chen
Hanqin Chen
NWNicholas Wallingford
Nicholas Wallingford
ACAndrew Craig
Andrew Craig
LSLarry S Sherman
Larry S Sherman

20 July 2009 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NWNicholas Wallingford
Nicholas Wallingford
BPBertrand Perroud
Bertrand Perroud
QGQian Gao
Qian Gao
ACAnna Coppola
Anna Coppola
EGErika Gyengesi
Erika Gyengesi
SDSabrina Diano
Sabrina Diano
The anorexigenic neuromodulator α-melanocyte–stimulating hormone (α-MSH; referred to here as α-MSH1–13) undergoes extensive posttranslational processing, and its in vivo activity is short lived due to rapid inactivation. The enzymatic control of α-MSH1–13 maturation and inactivation is incompletely understood. Here we have provided insight into α-MSH1–13 inactivation through the generation and analysis of a subcongenic mouse strain with reduced body fat compared with controls. Using positional cloning, we identified a maximum of 6 coding genes, including that encoding prolylcarboxypeptidase (PRCP), in the donor region. Real-time PCR revealed a marked genotype effect on Prcp mRNA expression in brain tissue. Biochemical studies using recombinant PRCP demonstrated that PRCP removes the C-terminal amino acid of α-MSH1–13, producing α-MSH1–12, which is not neuroactive. We found that Prcp was expressed in the hypothalamus in neuronal populations that send efferents to areas where α-MSH1–13 is released from axon terminals. The inhibition of PRCP activity by small molecule protease inhibitors administered peripherally or centrally decreased food intake in both wild-type and obese mice. Furthermore, Prcp-null mice had elevated levels of α-MSH1–13 in the hypothalamus and were leaner and shorter than the wild-type controls on a regular chow diet; they were also resistant to high-fat diet–induced obesity. Our results suggest that PRCP is an important component of melanocortin signaling and weight maintenance via control of active α-MSH1–13 levels.

30 April 2004 in Glia
Verified
Journal Article
Closed access
PDF file
TTTherese M.F. Tuohy
Therese M.F. Tuohy
NWNicholas Wallingford
Nicholas Wallingford
YLYing Liu
Ying Liu
FCFrank H. Chan
Frank H. Chan
TRTilat Rizvi
Tilat Rizvi
LSLarry S. Sherman
Larry S. Sherman

6 March 2002 in Glia
Verified
Journal Article
Closed access
PDF file
LSLarry S. Sherman
Larry S. Sherman
JSJaime N. Struve
Jaime N. Struve
RRReshma Rangwala
Reshma Rangwala
NWNicholas M. Wallingford
Nicholas M. Wallingford
TTTherese M.F. Tuohy
Therese M.F. Tuohy
CKCharles Kuntz
Charles Kuntz

5 March 2008 in Neuropsychopharmacology
Verified
Journal Article
Closed access
NWNicholas M Wallingford
Nicholas M Wallingford
Puspha SinnayahPuspha Sinnayah
Puspha Sinnayah
FBFrank P Bymaster
Frank P Bymaster
KGKishore M Gadde
Kishore M Gadde
RKRanga K Krishnan
Ranga K Krishnan
MCMichael A Cowley
Michael A Cowley